**Sup Table S1.** **Relationship between *AhR* mRNA expression and clinical biological parameters in a series of 29 gastric cancers including diffuse- and intestinal subtypes.**

Median range of gene mRNA expression levels; p value (Mann Whitney). ND, not determined

|  |  |  |
| --- | --- | --- |
| **All Tumors****n=29** | **Diffuse sub-type****n=13** | **Intestinal sub-type****n=16** |
|   | ***AhR*** |  | ***AhR*** |  | ***AhR*** |
| **GenderMale (n=13)Female (n=16)** | p=0.511.54 (0.55-3.33)1.35 (0.65-3.53) | **GenderMale (n=6)Female (n=7)** | p=0.811.51 (0.87-3.08)1.58 (1.22-2.01) | **GenderMale (n=7)Female (n=9)** | p=0.191.71 (0.89-2.84)1.16 (0.89-1.83) |
| **Age<60 years (n=9)>60 years (n=20)** | p=0.821.94 (0.55-3.35)1.80 (0.65-3.53) | **Age<60 years (n=8)>60 years (n=5)** | p=0.721.51 (0.87-2.01)1.58 (1.22-3.08) | **Age<60 years (n=1)>60 years (n=15)** | p=0.801.38 (0.89-1.83)1.16 (0.90-2.84) |
| **Smokingnegative (n=12)positive (n=10)** | p=0.851.77 (0.55-3.35)1.85 (0.82-3.53) | **Smokingnegative (n=4)positive (n=3)** | p=0.631.51 (0.87-1.63)1.58 (1.27-2.01) | **Smokingnegative (n=8)positive (n=7)** | p=0.741.19 (0.89-1.71)0.96 (0.9-1.55) |
| **Tumor invasion TT1-T2 (n=6)T3-T4 (n=23)** | p=0.211.45 (0.65-2.86)1.94 (0.55-3.53) | **Tumor invasionT1-T2 (n=2)T3-T4 (n=11)** | ND1.42 (1.27-1.58)1.53 (0.9-3.1) | **Tumor invasionT1-T2 (n=4)T3-T4 (n=12)** | ND0.93 (0.9-0.96)1.55 (0.89-2.84) |
| **Lymphatic invasionnegative (n=11)positive (n=17)** | p=0.111.25 (0.65-3.18)2.11 (0.55-3.53) | **Lymphatic invasionnegative (n=1)positive (n=12)** | ND1.531.53 (0.87-3.08) | **Lymphatic invasionnegative (n=10)positive (n=5)** | p=0.611.71 (0.65-3.18)1.94 (1.21-3.53) |
| **Metastasis Mnegative (n=24)positive (n=5)** | p=0.921.96 (0.55-3.53)2.1 (0.82-2.55) | **Metastasisnegative (n=9)positive (n=4)** | p=0.931.49 (0.87-3.08)1.58 (1.22-2.01) | **Metastasisnegative (n=15)positive (n=1)** | p=0.791.71 (0.89-2.84)1.19 (1.16-1.55) |
| **TNMI-II (n=16)III-IV (n=13)** | p=0.301.77 (0.54-3.35)2.11 (0.82-3.53) | **TNMI-II (n=5)III-IV (n=8)** | p=0.211.32 (0.87-1.9)1.6 (1.22-3.08) | **TNMI-II (n=11)III-IV (n=5)** | p=0.801.71 (0.89-1.83)1.19 (0.9-2.84) |
| **Vascular invasionnegative (n=9)positive (n=20)** | p=0.141.25 (0.82-2.96)2.05 (0.55-3.53) | **Vascular invasionnegative (n=3)positive (n=10)** | p>0.99991.53 (1.32-1.63)1.53 (0.87-3.08) | **Vascular invasionnegative (n=6)positive (n=10)** | p=0.791.21 (1.18-1.72)1.35 (0.89-2.84) |
| **Neural invasionnegative (n=6)positive (n=23)** | p=0.471.58 (0.90-2.86)1.94 (0.55-3.53) | **EPNnegative (n=2)positive (n=11)** | ND1.42 (1.27-1.58)1.53 (0.9-3.1) | **EPNnegative (n= 4)positive (n= 12)** | ND0.93 (0.9-0.96)1.55 (0.89-2.84) |